- Cancer Biology & Biomarkers
- Chromatography & Mass Spectrometry
- Contract Research, Clinical Trials and Outsourcing
- Drug Discovery
- Drug Targets
- Flow Cytometry
- Informatics & Lab Automation
- Ingredients, Excipients and Dosages
- Microbiology & RMMs
- NIR, PAT & QbD
- Raman Spectroscopy
- Screening, Assays & High-Content Analysis
- Thermal Processing
- Events & Workshops
Citius announces Phase 2a data for haemorrhoid treatment
2 February 2016 • Author: Victoria White
Citius Pharmaceuticals has announced top line data from the first Phase 2a clinical trial of hydrocortisone acetate and lidocaine hydrochloride in patents with grade I and II haemorrhoids.
The combination cream aims to become the first FDA-approved prescription product to treat haemorrhoids in the US.
In this randomized, double blind study of topical formulations of hydrocortisone (HC), lidocaine (L) and hydrocortisone + lidocaine (HC+L) were tested in patients with Grade I and II haemorrhoids. There have been no historical randomized, placebo-controlled studies of these two drugs used either individually or in combination to treat haemorrhoids. Therefore, this study’s objective was to obtain data to inform the design of future studies.
Within the first few days of treatment the highest concentration of the hydrocortisone + lidocaine product was directionally superior to the placebo as measured by the number of subjects experiencing a minimum of 2 levels improvement from baseline according to the Global Score of Disease Severity (GSDS) scale. This study was not powered to obtain statistical significance; however the data suggest that the combination product may also perform better than the HC or L alone. The trend of HC+L superiority over placebo was also generally consistent for the treatment of individual signs and symptoms of hemorrhoidal disease – bleeding, itching, pain and overall discomfort. In addition, no safety signal of note was recorded in the trial.
“We are pleased with the results of this study which was intended to test the hypothesis that a steroid and anesthetic drug combination can be an effective way to reduce the symptoms of heamorrhoids,” said Mr Leonard Mazur, Chairman and Chief Executive Officer of Citius Pharmaceuticals, Inc. “As expected, the data provides a positive directional signal and also indicate early reduction of symptoms. We look forward to submitting these results to the FDA as we move toward commercialisation of our product within this $1 billion market with unmet need.”
ABB Analytical Measurement ACD/Labs ADInstruments Ltd Advanced Analytical Technologies GmbH Analytik Jena AG Astell Scientific Ltd B&W Tek Bachem AG Bibby Scientific Limited Bio-Rad Laboratories BioNavis Ltd Biopharma Group Black Swan Analysis Limited CAPSUGEL NV Charles Ischi AG | Kraemer Elektronik Cherwell Laboratories CI Precision Cobalt Light Systems Coulter Partners CPC Biotech srl Dassault Systèmes BIOVIA DiscoverX Edinburgh Instruments Enterprise System Partners (ESP) Eurofins BioPharma Product Testing EUROGENTEC F.P.S. Food and Pharma Systems Srl GE Analytical Instruments IDBS JEOL Europe L.B. Bohle Maschinen + Verfahren GmbH Lab M Ltd. LabWare Linkam Scientific Instruments Limited MA Business Metrohm Molins Technologies Multicore Dynamics Ltd Nanosurf New England Biolabs, Inc. Ocean Optics Panasonic Biomedical Sales Europe B.V. PerkinElmer Inc ReAgent Russell Finex Limited Source BioScience Takara Clontech Tornado Spectral Systems Tuttnauer Viavi Solutions, Inc Watson-Marlow Fluid Technology Group Wickham Laboratories Limited Xylem Analytics YMC Europe GmbH Yusen Logistics